The DEA recently abandoned a proposal for placing five tryptamines as Schedule I under the Controlled Substances Act. Yet the agency is pushing forward to veto two psychedelic drugs named DOI and DOC with dubious evidence of their potentially nocive effects, as first reported by Psychedelic Spotlight.
Both DOI (dimethoxy-4-iodoamphetamine) and DOC (2,5-dimethoxy-4-chloroamphetamine) are hallucinogens and were first synthesized by the famous psychedelic researcher Alexander Shulgin. Both substances presumably hold subjective effects similar to LSD, though those of DOI and DOC may last longer and provide a more energetic feeling.
